Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
Date:12/3/2009

s receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Investor Relations Firm Access IR/PR and The Communications Strategy Group Announce Strategic Alliance
2. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
3. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
5. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
6. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
7. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
8. Access Pharmaceuticals CEO Interviewed on Financial Website
9. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
10. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
11. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Baird Healthcare Conference in New York.  Ingo Bank ... be making a presentation on PAREXEL and discussing business ... 2014. A live webcast of the discussion ... website at www.PAREXEL.com in the Upcoming Events ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2
... Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced today ... 2007 highlights, Major pipeline progress:, - ... cSSSI,achieves its pre-specified primary endpoint, as did the first, ... intravenous iclaprim in,cSSSI initiated, - First patients enrolled ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the management of ... SURGICAL IMPLANT is a biodegradable and fully,bioresorbable ...
... 13 Kansas has long,been known for its ... many have not realized, however, is that Kansas, ... far beyond the farm,-- namely, the scientific laboratory., ... and the,animal-health industry have positioned the state squarely ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... rainforests are often called the "lungs of the planet" because ... But the amount of carbon dioxide that rainforests absorb, or ... a paper published online this week (Feb 6 2013) by ... from the University of Exeter, the Met Office-Hadley Centre and ...
... A closer look at personalized or point-of-care healthcare ... in India organized and chaired by NJIT Distinguished ... Medicine and Biology Society (EMBS) International Special Topic ... the world, focused on topics ranging from 21st ...
... Virginia Commonwealth University Massey Cancer Center suggest that a ... potentially be an effective new therapy for several forms ... and mantle cell lymphoma (MCL). The study, ... showed that the experimental drug combination killed cancer cells ...
Cached Biology News:Lungs of the planet reveal their true sensitivity to global warming 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 3Experimental drug combination selectively destroys lymphoma cells 2
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Selective media for Salmonella...
Biology Products: